CN107693509A - SB FI 26 are preparing the application in treating breast cancer medicines - Google Patents
SB FI 26 are preparing the application in treating breast cancer medicines Download PDFInfo
- Publication number
- CN107693509A CN107693509A CN201711173187.5A CN201711173187A CN107693509A CN 107693509 A CN107693509 A CN 107693509A CN 201711173187 A CN201711173187 A CN 201711173187A CN 107693509 A CN107693509 A CN 107693509A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- cells
- mda
- cell
- mcf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of SB FI 26 to prepare the application in treating breast cancer medicines.SB FI 26 have identical construction unit (α truxillic acids) with horned artemisia ester alkali class compound, are tumour cell fatty acid transport protein (FABP5) inhibitor.In vitro and in vivo activity is tested, it is found that compound SB FI 26 can suppress the activity of FABP5 transhipment aliphatic acid, has significant inhibition to breast cancer cell MCF 7, ZR 75, MDA MB 468, MDA MB 231, MDA MB 453 propagation；Results of animal shows that SB FI 26 can suppress the transfer of human breast cancer in nude mice cell, reduces tumor tissues size.Do not reported in the treatment of breast cancer on SB FI 26, it is new antineoplastic that the compound, which is expected exploitation, is particularly used for the novel drugs for treating breast cancer, therefore have good development prospect.
Description
Technical field
The invention belongs to pharmaceutical technology field, specifically, is related to a kind of SB-FI-26 and is preparing treatment breast cancer medicines
In application.
Background technology
Breast cancer is one of most multiple malignant tumour of women.In the world, mammary gland in different regions, different crowd
Cancer is one of major cancers, especially relatively higher in developed country, breast cancer incidence.2016《Cancer
Statistics》Data show that there are 1,685,210 new cancer cases in the U.S. in 2015, and 595,690 patients can be because of cancer
And die, breast cancer is come out top with 29% ratio in the female cancer incidence of disease, and the death rate is only second to lung cancer and occupies second.Closely
Nian Lai, along with Chinese society rapid development of economy, industrialization, the quickening of urbanization process, the destruction of environment and increasingly
The change of serious Aging Problem, in addition people life style, the burden day of numerous malignant tumours including breast cancer
Become serious, serious threat the health of numerous residents.China women breast is disclosed early in China's tumour registration annual report data in 2013
The average age of gland cancer morbidity is 48.7 years old, has done sth. in advance 10 years than western countries, in women cancer occurred frequently, breast cancer has surpassed
More lung cancer turns into first.2016《Cancer Statistics in China, 2015》Statistical result show, 2009-
2011 Nian Jian China female cancer incidences of disease dramatically increase, and wherein breast cancer ranks first place position, and in increasing situation year by year.Cause
This, breast cancer is a kind of disease for having a strong impact on the physically and mentally healthy even crisis life of women.The therapeutic modality bag of breast cancer at present
Two methods of drug therapy and operative treatment are included, operative treatment is typically using excision breast, the serious body and mind for damaging women, medicine
It is larger to treat toxic side effect, easily produces resistance situation.
Breast cancer conventional therapy has at present：1st, operative treatment：Many patient the dead die from DISTANT METASTASES IN after mammary cancer surgery,
The strengthening vital QI to eliminate pathogenic factors treatment of traditional Chinese medicine is even more an important ring before and after mammary cancer surgery；2nd, radiotherapy；3rd, chemotherapy；4th, exempt from
Epidemic disease is treated：By transferring internal body system of defense function, to have the function that to prevent tumour growth and diffusion.Treatment side above
Though method has certain effect but curative effect is not good enough.
FAPB5 fatty acid binding proteins (FABPs) are referred to as the transport factor of lipid.They will be full containing high-affinity
It is combined together, and is transported it into cell with aliphatic acid and unrighted acid.FABP5 is a 15kDa cytoplasm egg
White matter, belong to FABP families.In addition to skin, FABP5 is also in placenta, heart, skeletal muscle, small intestine, kidney medulla and lung carat
Draw and attenuate in the endothelial cell of born of the same parents and goblet cell and detect expression.
SB-FI-26 once be used to increase intracerebral acid amides level, so as to produce analgesic effect, although SB-FI-26 is in brain
Cannboid transhipment in be used as FABP5 inhibitor, but its possibility on Cancerous disease influence it is unclear.It there is no relevant
Document report related to the research in terms of anti-breast cancer SB-FI-26.
The content of the invention
In view of this, the present invention is directed to the problem of above-mentioned, there is provided a kind of SB-FI-26 is preparing treatment breast cancer medicines
In application.
In order to solve the above-mentioned technical problem, the invention discloses a kind of SB-FI-26 in treatment breast cancer medicines are prepared
Using described medical compounds is SB-FI-26 (α-truxillic acid -1- naphthyl esters, α-truxillic acid-1-
Naphthyl ester, ChemDiv 8009-2334), shown in its structure following (I)：
Further, described SB-FI-26, which has, suppresses Luminal A type MCF-7 breast cancer cells, Luminal Type Bs
ZR-75 breast cancer cells, Basal type MDA-MB-468 breast cancer cells, Claudin-low type MDA-MB-231, HER2 classes
MDA-MB-453 cells.
Further, the SB-FI-26 can significantly inhibit all Cells Proliferation of Human Breast Cancer under 10~100 μM of concentration,
And more than 90% is reached to the proliferation inhibition rate of MCF-7 cells.
Further, the SB-FI-26 is under 10~100 μM of concentration, except that can significantly inhibit MCF-7 cells propagation, simultaneously
ZR-75 cells propagation can be significantly inhibited, and more than 70% is reached to the proliferation inhibition rate of ZR-75 cells；It can significantly inhibit
MDA-MB-468 cells are bred, and reach more than 80% to the proliferation inhibition rate of MDA-MB-468 cells；It can significantly inhibit
MDA-MB-231 cells are bred, and reach more than 80% to the proliferation inhibition rate of MDA-MB-231 cells；It can significantly inhibit
MDA-MB-453 cells are bred, and reach more than 80% to the proliferation inhibition rate of MDA-MB-453 cells.
Compared with prior art, the present invention can be obtained including following technique effect：
By carrying out In vitro and in vivo activity test to compound SB-FI-26, it is found that it is stronger SB-FI-26 has to FABP5
Inhibitory action, the cell lines such as breast cancer cell MCF-7, MDA-MB-231, MDA-MB-468, ZR-75, MDA-MB-453 are bred
With obvious inhibition, and the Compound Cytotoxicity is smaller, has good DEVELOPMENT PROSPECT, and the compound is expected out
Send out as the new novel drugs for being used to treat breast cancer.
Certainly, any product for implementing the present invention it is not absolutely required to reach all the above technique effect simultaneously.
Brief description of the drawings
Accompanying drawing described herein is used for providing a further understanding of the present invention, forms the part of the present invention, this hair
Bright schematic description and description is used to explain the present invention, does not form inappropriate limitation of the present invention.In the accompanying drawings：
Fig. 1 is expression of the Western blot analyses FABP5 of the present invention in different cell lines；
Fig. 2 is that SB-FI-26 of the present invention determines to fatty acid transport protein FABP5 affinity；
Fig. 3 is fragmentation effect curves of the SB-FI-26 of the present invention to MCF-7 cells；
Fig. 4 is breast cancer cell scratch test of the present invention；
Fig. 5 is breast cancer cell Soft Agar Assay of the present invention；
Fig. 6 is breast cancer cell Transwell migration tests of the present invention.
Embodiment
Describe embodiments of the present invention in detail below in conjunction with embodiment, thereby to the present invention how application technology hand
Section can fully understand and implement according to this to solve technical problem and reach the implementation process of technical effect.
The invention discloses a kind of SB-FI-26 to prepare the application in treating breast cancer medicines, wherein, described medicine
Compound be SB-FI-26 (α-truxillic acid -1- naphthyl esters, α-truxillic acid-1-naphthyl ester,
ChemDiv 8009-2334), shown in its structure following (I)：
Expression analysis of the embodiment 1FABP5 in cell
The present invention analyzes FABP5 in breast cancer cell MCF-7 and normal human cells by Western blot methods
Expression analysis in HUMA121.As a result show that FABP5 expression quantity is than normal cell HUMA121 cells in breast cancer cell MCF-7
The high result of expression quantity such as Fig. 1；It is as shown in Figure 2 that SB-FI-26 can suppress MCF-7 proliferation results.
Embodiment 2FABP5 transports fatty acid analysis
The intake of aliphatic acid is detected using the Novel BODIPY flourescent dye of red fluorescence mark.After BODIPY is added, carefully
The fluorescent strength determining of born of the same parents is the absorption of aliphatic acid.In suppression and competitive assay, the unmarked lead compound of various concentrations
SB-FI-26 (50-200 μM) and the BODIPY of same concentrations are added directly in MCF-7 cells, as a result see Fig. 3.As a result table
Affinity costant Ki=1.69 ± 0.15 μM of bright SB-FI-26 bindings FABP5 protein.
The cell proliferation experiment of embodiment 3
Experimental principle：CCK analytic approach one kind is based on WST-8 (2- (nitrobenzene of 2- methoxyl groups -4) -3- (4- nitrobenzene) -5-
(2,4- disulfobenzene) -2H- tetrazolium monosodium salts), WST-8 is a kind of compound similar to MTT, is existed in electronics coupled reagent
In the case of, it can be reduced by some Intramitochondrial dehydrogenases and generate orange-yellow water miscible formazan dyestuff.Utilize enzyme mark
Optical density OD values at instrument measure 450nm, to reflect number of viable cells, so as to determine the killing of compound on tumor cell effect
Fruit.
Experimental procedure：
1) logarithmic phase cell is collected, adjusts concentration of cell suspension, 100 μ L are added per hole, bed board makes the cell density to be measured be
96 orifice plates are placed on 5%CO by 10000/hole (edge hole is filled with sterile PBS)2, 24h is incubated in 37 DEG C of incubators, to cell
Individual layer is paved with bottom hole；
2) the SB-FI-26 solution of various concentrations gradient is added.General 5-7 gradient, per the μ L of hole 5, if 3-5 parallel hole；
3) 5%CO2, 37 DEG C are incubated 24 hours, are observed under inverted microscope；
4) 10 μ L CCK-8 solution are added per hole, continue to cultivate 1-4h.The light absorption value in each hole is measured at 450nm.
Because FABP5 too high expression in the cancer cell related to hormone, we attempt this with a variety of cancer cells
The inhibiting tumor cell activity of kind compound, the cancer cell used have PC3, PC3M, MCF-7, MDA-231.Pass through MCF-7 cell experiments
To determine the toxicity size of such a compound.
Experimental result：As a result it is as shown in table 1.SB-FI-26 is relatively low to normal cell HUMA121 cytotoxicity, SB-FI-
26 pairs of MCF-7, MDA-MB-231, MDA-MB-468, ZR-75, MDA-MB-453 breast cancer cells have obvious Inhibit proliferaton
Effect.
Table 1SB-FI-26 is to the inhibitory activity of breast cancer cell (IC50, μM)
The cell scratch experiment of embodiment 4
Experimental principle：
Determine cell migration campaign and repair ability, on the attached cell for the individual layer cultivated in vitro, existed with micro pipette tips
The middle section line of cell growth, the cell of middle body is removed, continue culture to appropriate time, whether is observation periphery cell
Migrate the growth transfer ability for judging cell with this to central cut area.
Experimental procedure：
1) cell suspension is prepared.
2) at the 6 orifice plate back sides, 5 straight lines is drawn with ruler, cross via, mono- line of about 0.5-1cm.
3) appropriate cell suspension (being paved with overnight), the mistake in 37 DEG C, 5%CO2 incubator are added into 6 orifice plates
Night cultivates.
4) after cell attachment and after being paved with, culture medium in hole is removed, according to 6 orifice plate back side straight lines, with yellow pipette tips in hole
Inside rule.
5) wash cell 3 times with PBS, remove the cell under drawing, add culture medium.
6) in 37 DEG C, 5%CO2Incubator in cultivate, be sampled in 0h, 6h, 12h, 24h, take pictures, measure iuntercellular
Distance, compare cell migration rates.
Experimental result：As a result it is as shown in Figure 4.SB-FI-26, which has, suppresses the migration of MCF-7 breast cancer cells and invasion and attack effect.
The soft-agar cloning of embodiment 5 forms experiment
Experimental principle：
Cell is allowed to be in not adherent and unicellular, analogue body inner cell is in half soliqueous situation, in this state
The ability of lower detection cell migration.
Experimental procedure：
1) culture medium that 2mL contains 2% low melting point gel is added into 6 orifice plates, in 4 DEG C of preculture 20min.
2) cell suspension is prepared, cell count is carried out using blood counting chamber, 5000 cells is added per hole.
3) cell suspending liquid is mixed with 1% low melting point gel.
4) take said mixture 2mL to be placed in above 6 orifice plates of preculture, 10min is cultivated in 4 DEG C.
5) by 6 orifice plates in 37 DEG C, 5%CO2Incubator in cultivate 4 weeks.
6) after 4-5 weeks, into 6 orifice plates adding 0.5mLMTT (5mg/mL) carries out cell dyeing, in 37 DEG C, 5%CO2Training
Support and counted after being cultivated 4 hours in case.
Experimental result：As a result it is as shown in Figure 5.Normal cell Human 121 forms 0 clone, and untreated MCF-7 is formed
67 clones, suppress MCF-7 formation clones after adding SB-FI-26.
The cell invasion of embodiment 6 is tested
Experimental principle：
Transwell cells are put into culture plate by cell migration with Matrigel, and small interior deserves to be called room, claims in culture plate
Lower room, levels nutrient solution are separated by with polycarbonate membrane, by the cell kind of research in upper interior, due to polycarbonate membrane have it is penetrating
Property, the composition in lower floor's nutrient solution can have influence on upper chamber inner cell, the poly- carbonic acid using different pore size and Jing Guo different disposal
Ester film, it is possible to co-cultured, cell chemotaxis, cell migration, the research of cell invasion etc..
Experimental procedure：
1) colloidal sol, 4 DEG C are transferred to from -20 DEG C treat that it dissolves naturally using preceding.
2) it is 5 × 10 to prepare cell suspension to concentration4Cells/ml (uses serum free medium).
3) basilar memebrane (operating on ice) is coated with, with the cold cell culture medium Matrigel glue (10mg/ml of serum-free
To 5mg/ml)), dilution glue is added in 24-well transwell upper chambers, 37 DEG C are incubated transwell at least 4-5h.
4) aquation basilar memebrane, gel is rinsed with serum free medium.
5) upper chamber adds 500ul cell suspensions, and 1000ul cell culture mediums (10%FBS) and chemoattractant are added in lower room.
6) in 37 DEG C, 5%CO2Incubator in cultivate 24h.
7) wipe the non-invasion cell above upper chamber with cotton swab and use PBS.
8) 0.2% crystal violet solution is added into 24 orifice plates, cell is placed in one, makes film submergence in the medium, 37
Taken out after DEG C 10min, PBS, 37 DEG C of dryings.
9) 4 visuals field are diametrically taken, are taken a picture, are counted.
Experimental result：As a result it is as shown in Figure 6.SB-FI-26, which has, to be significantly inhibited (more than 2 times) MCF-7 breast cancer cells and invades
The effect of attacking.
Embodiment 7：Inhibitory activity of the SB-FI-26 to breast cancer solid tumor nude mice model
It will amount to 30 purchased from nude mice of the Sichuan up to large zoopery Co., Ltd before experiment, raise to 5 week old.By MDA-
MB-231 cells (5 × 104Individual cell/μ L) it is subcutaneously injected into nude mouse, after raising nude mice for a period of time, grow an about 2mm left sides
After the tumour of right size, nude mice is randomly divided into 3 groups, every group 10, is respectively：1 group is blank control group (physiological saline
150ml/kg), 2 groups are SB-FI-26 low dose groups (50mg/kg), and 3 groups are SB-FI-26 high doses group (100mg/kg), daily
It is administered once, is administered 4 weeks altogether.After treatment end, animal is weighed, compares each group tumour growth situation.
Table 2SB-FI-26 is to inhibiting rate inside tumour cell
As shown in table 2, test result indicates that the SB-FI-26 in the range of finite concentration has necessarily to nude mice in-vivo tumour
Inhibitory action.In summary test result indicates that compound SB-FI-26 is the inhibitor of good FABP5 protein, it has
The effectively effect of killing breast cancer cell, it is a kind of compound of potential anti-breast cancer, and is likely to become treatment breast cancer
A kind new medicine.
Embodiment 8
MCF-7 Human Breast Cancer Cells are inoculated in 25cm2In blake bottle, add containing 10% hyclone, penicillin, strepto-
Each 100U of element RPMI1640 nutrient solutions 5ml.In 37 DEG C, the CO that volume fraction is 0.052Sterile training in saturated humidity incubator
Support.Administration packet, cell controls group：The μ l of 100 μ l+ cell suspensions of RPMI1640 nutrient solutions 100, blank group：RPMI1640 is cultivated
The μ l of liquid 200, taxol group (A)：Paclitaxel concentration is respectively 0.01,0.1,1.0,10,50 μ g/ml, SB-FI-26 groups (B)：SB-
FI-26 concentration is respectively 12.5,125,250,500,1000 μ g/ml, lobaplatin group (C)：Lobaplatin concentration is respectively 4,8,16,32,
64 μ g/ml, each hole cumulative volume are：200μl.
Inhibitory action of the table 3SB-FI-26 drug combinations to MCF-7
Shown by the result of table 3, it is thin that processing human breast carcinoma MCF-7 is used in combination with taxol and lobaplatin respectively in SB-FI-26 groups
After born of the same parents 48h, its growth to MCF-7 Human Breast Cancer Cells has obvious inhibitory action, and is in certain dose-dependence, with
The increase of drug concentration, cytoactive and multiplication capacity are gradually reduced, i.e., inhibiting rate increases.Show that SB-FI-26 combines Japanese yew
The inhibitory action of alcohol and lobaplatin is better than taxol and lobaplatin list medicine group (P ＜ 0.05), and SB-FI-26 is to taxol and lobaplatin for display
Chemotherapy there is sensitization.
Some preferred embodiments of invention have shown and described in described above, but as previously described, it should be understood that invention is not
Form disclosed herein is confined to, is not to be taken as the exclusion to other embodiment, and available for various other combinations, modification
And environment, and can be carried out in the scope of the invention is set forth herein by the technology or knowledge of above-mentioned teaching or association area
Change., then all should be in power appended by invention and the change and change that those skilled in the art are carried out do not depart from the spirit and scope of invention
In the protection domain that profit requires.
Claims (4)
1. a kind of SB-FI-26 is preparing the application in treating breast cancer medicines, it is characterised in that described medical compounds is
SB-FI-26 (α-truxillic acid -1- naphthyl esters, α-truxillic acid-1-naphthyl ester, ChemDiv
8009-2334), shown in its structure following (I)：
2. application according to claim 1, it is characterised in that described SB-FI-26, which has, suppresses Luminal A types
MCF-7 breast cancer cells, Luminal Type B ZR-75 breast cancer cells, Basal type MDA-MB-468 breast cancer cells,
Claudin-low type MDA-MB-231, HER2 class MDA-MB-453 cells.
3. application according to claim 2, it is characterised in that the SB-FI-26, can be notable under 10~100 μM of concentration
Suppress all Cells Proliferation of Human Breast Cancer, and more than 90% is reached to the proliferation inhibition rate of MCF-7 cells.
4. application according to claim 1, it is characterised in that the SB-FI-26 is under 10~100 μM of concentration, except can show
Write and suppress MCF-7 cells propagation, while ZR-75 cells propagation can be significantly inhibited, and the proliferation inhibition rate of ZR-75 cells is reached
To more than 70%；MDA-MB-468 cells propagation can be significantly inhibited, and the proliferation inhibition rate of MDA-MB-468 cells is reached
More than 80%；MDA-MB-231 cells propagation can be significantly inhibited, and the proliferation inhibition rate of MDA-MB-231 cells is reached
More than 80%；MDA-MB-453 cells propagation can be significantly inhibited, and the proliferation inhibition rate of MDA-MB-453 cells is reached
More than 80%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711173187.5A CN107693509A (en) | 2017-11-22 | 2017-11-22 | SB FI 26 are preparing the application in treating breast cancer medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711173187.5A CN107693509A (en) | 2017-11-22 | 2017-11-22 | SB FI 26 are preparing the application in treating breast cancer medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107693509A true CN107693509A (en) | 2018-02-16 |
Family
ID=61180536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711173187.5A Pending CN107693509A (en) | 2017-11-22 | 2017-11-22 | SB FI 26 are preparing the application in treating breast cancer medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107693509A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4065099A4 (en) * | 2019-11-25 | 2023-11-29 | The Research Foundation for The State University of New York | Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017103625A1 (en) * | 2015-12-18 | 2017-06-22 | The University Of Liverpool | Cancer treatment |
-
2017
- 2017-11-22 CN CN201711173187.5A patent/CN107693509A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017103625A1 (en) * | 2015-12-18 | 2017-06-22 | The University Of Liverpool | Cancer treatment |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4065099A4 (en) * | 2019-11-25 | 2023-11-29 | The Research Foundation for The State University of New York | Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Tetrandrine suppresses cancer angiogenesis and metastasis in 4T1 tumor bearing mice | |
| CN107531768A (en) | Anti-senescence compounds and application thereof | |
| CN107106580A (en) | The composition for the treatment of cancer stem cell | |
| CN102552908B (en) | Pharmaceutical composition containing artemisinin, artemisinin derivatives and Bcl-2 inhibitor and application thereof | |
| CN104906558B (en) | The pharmaceutical composition containing ulinastatin for the treatment of cervical cancer | |
| CN109568299A (en) | Ambroxol purposes in preparing tumor chemotherapeutic drug Synergistic preparations | |
| CN104586873B (en) | Application of the oroxin A in treating cancer medicine is prepared | |
| CN102688493B (en) | Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof | |
| CN101940569B (en) | Medicament composition containing sorafenib, artemisinin and artemisinin derivative and application thereof in preparing medicament for treating cancer | |
| CN109602752B (en) | Triptolide is in induction cancer cell autophagy and hdac inhibitor is cooperateed with to treat the application in tumour | |
| CN100443080C (en) | Medicinal composition for preventing and treating cancer diseases | |
| CN109419803A (en) | Cell autophagy inhibitor and Afatinib pharmaceutical composition and its purposes in preparation tumour Synergistic preparations | |
| CN107693509A (en) | SB FI 26 are preparing the application in treating breast cancer medicines | |
| CN103142774B (en) | Application of total saponin extract of lobedfruit schizocapsarhizome in treatment of liver cancer and nasopharyngeal carcinoma | |
| CN104706649A (en) | Application of oroxyloside to preparation of anti-tumor drugs | |
| CN107028935A (en) | Application of the wogonin in treatment clear-cell carcinoma medicine is prepared | |
| CN108403690A (en) | It is a kind of inhibit melanoma cells proliferation drug and its application | |
| CN106955292A (en) | A kind of pharmaceutical composition and purposes for treating the cancer of the esophagus | |
| Feng et al. | Compound C17 inhibits the lung metastasis of breast cancer. | |
| CN106924225A (en) | Application of the magnolol in antineoplastic sensitizer is prepared | |
| CN112755033A (en) | Application of retinoic acid compound in preparation of anti-liver cancer medicine | |
| CN102631345A (en) | Medicine composition for reversing cancer cell tolerance and application of medicine composition | |
| CN102440987B (en) | Drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof | |
| CN106924253A (en) | Application of 8- the third dicyan jamaicins in antineoplastic sensitizer is prepared | |
| CN107198688A (en) | Application of the traditional Chinese medicine monomer lycorine in treatment breast cancer medicines are prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180216 |